VTE recurrence in patients with inherited deficiencies of natural anticoagulants

Thrombosis and Haemostasis

Volumn 101, Issue 1, 2009, Pages 5-6

  Dentali, Francesco ^a   Gianni, Monica ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b Hospital of Tradate   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; ANTITHROMBIN III DEFICIENCY; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; GENETIC PREDISPOSITION; GENETICS; INCIDENCE; NOTE; PEDIGREE; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ANTICOAGULANTS; ANTITHROMBIN III DEFICIENCY; DISEASE-FREE SURVIVAL; GENETIC PREDISPOSITION TO DISEASE; HEMORRHAGE; HUMANS; INCIDENCE; PEDIGREE; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 60849134007     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-11-0763     Document Type: Editorial

References (18)

1. Prandoni P, Lensing AWA, Cogo A, et al. The longterm clinical course of acute deep venous thrombosis, Ann Intern Med 1996; 125: 1-7.
2. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism - A population-based cohort study. Arch Intern Med 2000; 160: 761-768.
3. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
4. Prandoni P. Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
5. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-611.
6. Kearon C, Kahn S. Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2008; 133: 454S-545S.
7. Palareti G, Cosmi B, Legnani C, et al; PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy, N Engl J Med 2006; 355: 1780-1789.
8. Prandoni P. Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955-960.
9. Eichinger S. Weltermann A. Minar E, et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164: 92-96.
10. McRae S, Tran H, Schulman S, et al. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006; 368: 371-378.
11. Ho WK, Hankey GJ, Quinlan DJ, et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166: 729-736.
12. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-3544.
13. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation delects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358.
14. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526.
15. Christiansen SC, Cannegieter S, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. I Am Med Assoc 2005; 293: 2352-2361.
16. Brouwer JL, Lijfering, LM, ten Kate MI, et al. High long term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 2009; 101:93-99.
17. Brouwer JL, Veeger NJ, Schaaf W, et al. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol 2005; 128: 703-710.
18. Lensen RP, Rosendaal FR, Koster T, et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1996; 88: 4205- 4208.